Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
(OP:
BNXTF
)
0.4886
UNCHANGED
Streaming Delayed Price
Updated: 9:36 AM EST, Dec 11, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
70
Open
0.4886
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.4886
Today's Range
0.4886 - 0.4886
52wk Range
0.2101 - 0.7856
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
December 09, 2025
Via
ACCESS Newswire
BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
December 01, 2025
Via
ACCESS Newswire
Performance
YTD
+71.1%
+71.1%
1 Month
-7.6%
-7.6%
3 Month
-17.3%
-17.3%
6 Month
+18.6%
+18.6%
1 Year
+132.6%
+132.6%
More News
Read More
BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
November 20, 2025
Via
ACCESS Newswire
BioNxt Reports “Intention to Grant” Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
November 04, 2025
Via
PressReach
Topics
Intellectual Property
BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
November 04, 2025
Via
ACCESS Newswire
BioNxt Reports “Readiness to Grant” Patent Notification from the Eurasian Patent Organization
October 30, 2025
Via
PressReach
Topics
Intellectual Property
BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
October 30, 2025
Via
ACCESS Newswire
BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug
October 22, 2025
Via
PressReach
Topics
Intellectual Property
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
October 21, 2025
Via
PressReach
Topics
Intellectual Property
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
October 21, 2025
Via
ACCESS Newswire
BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
October 09, 2025
Via
ACCESS Newswire
BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
October 02, 2025
Via
ACCESS Newswire
BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization
September 29, 2025
Via
ACCESS Newswire
Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals
September 19, 2025
Via
ACCESS Newswire
BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development
September 15, 2025
Via
ACCESS Newswire
BioNxt Solutions Completes Up-Listing to The OTCQB Market
September 05, 2025
Via
ACCESS Newswire
Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt
September 02, 2025
Via
ACCESS Newswire
BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline
August 20, 2025
Via
ACCESS Newswire
BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
August 05, 2025
Via
ACCESS Newswire
BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation
July 23, 2025
Via
ACCESS Newswire
BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology
July 08, 2025
Via
ACCESS Newswire
BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
July 07, 2025
Via
ACCESS Newswire
BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets
June 23, 2025
Via
ACCESS Newswire
BioNxt Solutions Provides Bi-weekly MCTO Status Report
May 29, 2025
Via
ACCESS Newswire
BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent
May 23, 2025
Via
ACCESS Newswire
Frequently Asked Questions
Is BNXTF publicly traded?
Yes, BNXTF is publicly traded.
What exchange does BNXTF trade on?
BNXTF trades on the OTC Traded
What is the ticker symbol for BNXTF?
The ticker symbol for BNXTF is BNXTF on the OTC Traded
What is the current price of BNXTF?
The current price of BNXTF is 0.4886
When was BNXTF last traded?
The last trade of BNXTF was at 12/11/25 09:36 AM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.